AR059594A1 - Derivados de 2,4-diaminopirimidinas - Google Patents

Derivados de 2,4-diaminopirimidinas

Info

Publication number
AR059594A1
AR059594A1 ARP070100726A ARP070100726A AR059594A1 AR 059594 A1 AR059594 A1 AR 059594A1 AR P070100726 A ARP070100726 A AR P070100726A AR P070100726 A ARP070100726 A AR P070100726A AR 059594 A1 AR059594 A1 AR 059594A1
Authority
AR
Argentina
Prior art keywords
piperazin
benzo
ylamino
trifluoromethyl
phenylamino
Prior art date
Application number
ARP070100726A
Other languages
English (en)
Inventor
Ingelheim Internati Boehringer
Harald Engelhardt
Stephan Karl Zahn
Heinz Stadtmueller
Anke Baum
Flavio Solca
Martin Steegmaier
Jens Juergen Quant
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR059594A1 publication Critical patent/AR059594A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Reivindicacion 1: Compuestos de la formula general (1) en donde significan X O o N, y Y -CH2- o C=O, y R1 y R1' en cada caso independientemente entre sí, hidrogeno o un radical eventualmente sustituido una o varias veces seleccionado del grupo constituido por alquiloC1-5, cicloalquilo C3-6, arilo, heterociclilo y heteroarilo, pudiendo ser el o los sustituyentes iguales o diferentes y se seleccionan del grupo constituido por halogeno, -ORa, -C(=O)Ra, -C(=O)ORa, -C(=O)NRaRa, -NRaRa, - NRaC(=O)Ra, -NRaC(=O)ORa, -NRaC(=O)NRaRa, -NRaSO2Ra, -N=CRaRa, -SRa, -SORa, -SO2Ra, -SO2NRaRa, -NRaSO2NRaRa, -OSO2NRaRa y pseudohalogeno, o eventualmente los R1' que se encuentran en el mismo átomo de C pueden formar conjuntamente un anillo cicloalquílico C3-7, o eventualmente R1 puede estar unido con un R1' formando un puente alquílico comun de 3-6 miembros, saturado o parcialmente insaturado, el cual puede contener eventualmente uno a dos heteroátomos, y R2 un radical heterociclilo eventualmente sustituido una o varias veces, pudiendo ser el/los sustituyentes iguales o diferentes y se seleccionan del grupo constituido por alquiloC1-5, alquenilo C2-5, alquinilo C2-5, cicloalquil C3-6-alquilo C0-3 y R3 hidrogeno o alquilo C1-3 o R2 y R3 forman conjuntamente un anillo heterociclilo eventualmente una o varias veces sustituido, el cual eventualmente puede contener uno a dos heteroátomos, pudiendo ser el/los sustituyentes iguales o distintos y se seleccionan del grupo constituido por alquilo C1-5, alquenilo C2-5, alquinilo C2-5 y cicloalquil C3-6-alquilo C0-3 o un sustituyente adecuado seleccionado del grupo constituido por halogeno, -ORa, -C(=O)Ra, -C(=O)ORa, -C(=O)NRaRa, -NRaRa, -NRaC(=O)Ra, -NRaC(=O)ORa, - NRaC(=O)NRaRa, -NRaSO2Ra, -N=CRaRa, -SRa, -SORa, -SO2Ra, -SO2NRaRa, -NRaSO2NRaRa, -OSO2NRaRa y pseudohalogeno, y R4 en cada caso independientemente entre sí un radical seleccionado del grupo constituido por halogeno, NO2, -ORa, -C(=O)Ra, -C(=O)ORa, - C(=O)NRaRa, -NRaRa, -NRaCORa, -NRaC(=O)ORa, -NRaC(=O)NRaRa, -NRaC(=O)ONRaRa, -NRaSO2Ra, -N=CRaRa, -SRa, -SORa, -SO2Ra, -SO2NRaRa, -NRaSO2NRaRa, -OSO2NRaRa y pseudohalogeno; y R5 hidrogeno, halogeno, alquilo C1-3, alquenilo C2-3, alquinilo C2-3, halogeno-alquilo C1-3, -ORa o pseudohalogeno, y R6 en cada caso independientemente entre sí, un radical seleccionado del grupo constituido por halogeno, alquilo C1-3, -ORa y pseudohalogeno, y Ra en cada caso independientemente entre sí, hidrogeno o un radical seleccionado del grupo constituido por alquilo C1-8 eventualmente sustituido, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-10, arilo, heterociclilo y heteroarilo, pudiendo ser el/los sustituyentes iguales o diferentes y se seleccionan del grupo constituido por halogeno, -NH2, -OH y pseudohalogeno; y m es 0, 1 o 2; y n en cada caso independientemente entre sí, 0, 1 o 2, eventualmente en forma de sus tautomeros, sus racematos, sus enantiomeros, sus diastereoisomeros y sus mezclas, así como eventualmente sus sales farmacologicamente tolerables, con la condicion de que están excluidos 2-(2-metoxi-4-piperazin-1-il-fenilamino)-4-(3,3-dimetil-5-oxo-2,3,4,5- benzo[°][1,4]oxazepin-6-ilamino-5-trifluormetil-pirimidina, 2-(2-metoxi-4- piperazin-l-il-fenilamino)-4-((S)-4-oxo-2,3,10,10a-tetrahidro-1H,4H-9-oxa-3a-aza-benzo[°]azulen-5-ilamino-5-trifluormetil-pirimidina, 2-[4-(4-etil-piperazin-1-il)-2-metoxi-fenilamino]-4-((S)-4-oxo-2,3,10,10a-tetrahidro-1H,4H-9-oxa-3a-aza- benzo[°]azulen-5-ilamino-5-trifluormetil-pirimidina, 2-[4-(4-metil-piperazin-1-il)-2-metoxi-fenilamino]-4-((S)-4-oxo-2,3,10,10a tetrahidro-1H,4H-9-oxa-3a-aza-benzo[°]azulen-5-ilamino-5-trifluormetil-pirimidina, 3,3-dimetil-6-{2-[4-(4-metil-piperazin- 1-il)-fenilamino]-5-trifluormetil-pirimidin-4-ilamino}-3,4-dihidro-2H-benzo[°][1,4]oxazepin-5-ona, 6-{2-[4-(4-etil-piperazin-1-il)-fenilamino]-5-trifluormetil-pirimidin-4-ilamino}-3,3-dimetil-3,4-dihidro-2H-benzo[°][1,4]oxazepin-5-ona; 3,3-dimetil-6- {2-[4-(4-prop-2-inil-piperazin-1-il)-fenilamino]5trifluometil-pirimidin-4-ilamino}-3,4-dihidro-2H-benzo[°][1,4]oxazepin-5-ona, 6-{2-[4-(4-isopropil-piperazin-1-il)-fenilamino]-5-trifluormetil-pirimidin-4iIamino}-3,3-dimetil-3,4-dihidro-2H- benzo[°][1,4]oxazepin-5-ona, (S)-3-metil-6-[2-(4-piperazin-1-il-fenilamino)-5-trifluormetil-pirimidin-4-ilamino]-3,4-dihidro-2H-benzo[°][1,4]oxazepin-5-ona, (S)-3-metil-6-{2[4-(4-metil-piperazin-1-iI)-fenilamino]-5-trifluormetiI-pirimidin-4-ilamino}- 3,4-dihidro-2H-benzo[°][1,4]oxazepin-5-ona, (S)-6-{2-[4-(4-isopropil-piperazin-1-il-fenilamino]-5-trifluormetil-pirimidin-4-ilamino}-3-metil-3,4-dihidro-2H-benzo[°][1,4]oxazepin-5-ona, (S)-3-metil-6-{2-[4-(4-prop-2-iniI-piperazin-1-il)-fenilamino]-5- trifluormetil- pirimidin-4-ilamino}-3,4-dihidro-2H-benzo[°][1,4]oxazepin-5-ona, (S)-3-etil-6-[2-(4-piperazin-1-il-fenilamino)-5-trifluormetil-pirimidin-4-ilamino]-3,4-dihidro-2H-benzo[°][1,4joxazepin-5-ona, (S)-6-[2-(4-piperazin-1-il-fenilamino)-5- trifluormetil-pirimidin-4-ilamino]-3-propil-3,4-dihidro-2H-benzo[°][1,4]oxazepin-5-ona, (S)-6-{2-[4-(4-prop-2-inil-piperazin-1-il)-fenilamino]-5-trifluormetil-pirimidin-4-ilamino}-1,2,3,11a-tetrahidro-10H-benzo[e]pirrolo[1,2-a][1,4}diazepin-5,11- diona, (S)-6-{2-[4-(4-etil-piperazin-1-il)-fenilamino]-5-trifluormetil-pirimidin-4-ilamino}-1,2,3,11a-tetrahidro-10H-benzo[e]pirrolo[1,2-a][1,4]diazepin-5,11-diona, (S)-6-{2-[4-(4-isobutil-piperazin-1-il)-fenilamino]-5-trifluormetil-pirimidin-4- ilamino}-1,2,3,11a-tetrahidro-10H-benzo[e]pirrolo[1,2-a][1,4]diazepin-5,11-diona, (S)-6-{2-[4-(4-metil-piperazin-1-il)-fenilamino]-5-trifluormetil-pirimidin-4-ilamino}-1,2,3,11a-tetrahidro-10H-benzo[e]pirrolo[1,2-a][1,4]diazepin-5,11-diona, 6-{2-[4- (4-etil-piperazin-1-il)-fenilamino]-5-trifluormetil-pirimidin-4-ilamino}-3,3-dimetil-3,4-dihidro-1H-benzo[e][1,4]diazepin-2,5-diona, 3,3-dimetiI-6-{2-[4-(4-metil-piperazin-1-il)-feniIamino]-5-trifluormetiI-pirimidin-4-ilamino} -3,4-dihidro-1H- benzo[e][1,4]diazepin-2,5-diona, 6-{2-[4-(4-isopropil-piperazin-1-il)-feniIamino]-5-trifluormetiI-pirimidin-4-ilamino}-3,3-dimetil-3,4-dihidro-1H-benzo[e][1,4]diazepin-2,5-diona, 3,3-dimetil-6-{2-[4-(4-prop-2-inil-piperazin-1-i1l-fenilamino]-5- trifluormetil-pirimidin-4-ilamino}-3,4-dihidro-1H-benzo[e][1,4]diazepin-2,5-diona, (S)-6-{2-[4-(4-isopropil-piperazin-1-il)-fenilamino]-5-trifluormetil-pirimidin-4-ilamino}-1,2,3,11a-tetrahidro-10H-benzo[e]pirrolo[1,2-a][1,4]diazepin-5,11-diona, (S)- 6-{2-[4-(4-isopropil-piperazin-1-il)-fenilamino]-5-trifluormetil-pirimidin-4-ilamino}-3-metil-3,4-dihidro-1H-benzo[e][1,4]diazepin-2,5-diona, (S)-3-metil-6-{2-[4-(4-metil-piperazin-1-il)-fenilamino]-5-trifluormetil-pirimidin-4-ilamino}-3,4-dihidro- 1H-benzo[e][1,4]diazepin-2,5-diona, (S)-3-metil-6-{2-[4-(4-prop-2-inil-piperazin-1-il)-fenilamino]-5-trifluormetil-pirimidin-4-ilamino}-3,4-dihidro-1H-benzo[e][1,4]diazepin-2,5-diona, (S)-6-{2-[4-(4-etil-piperazin-1-il)-fenilamino]-5-trifluormetil- pirimidin-4-ilamino}-3-metil-3,4-dihidro-1H-benzo[e][1,4]diazepin-2,5-diona y {(S)-2,5-dioxo-6-[2-(4-piperazin-1-il-fenilamino)-5-trifluormetil-pirimidin-4-ilamino]-2,3,4,5-tetrahidro-1H-benzo[e][1,4]diazepin-3-il}-metiléster del ácido acético.
ARP070100726A 2006-02-22 2007-02-21 Derivados de 2,4-diaminopirimidinas AR059594A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06110303 2006-02-22

Publications (1)

Publication Number Publication Date
AR059594A1 true AR059594A1 (es) 2008-04-16

Family

ID=36997219

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100726A AR059594A1 (es) 2006-02-22 2007-02-21 Derivados de 2,4-diaminopirimidinas

Country Status (7)

Country Link
US (1) US7569561B2 (es)
EP (1) EP1989198B1 (es)
JP (1) JP5306830B2 (es)
AR (1) AR059594A1 (es)
CA (1) CA2638095C (es)
TW (1) TW200804364A (es)
WO (1) WO2007096351A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2669111C (en) 2006-10-23 2016-04-12 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
AU2008258560C1 (en) * 2007-06-08 2014-04-10 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
AR066911A1 (es) * 2007-06-08 2009-09-23 Janssen Pharmaceutica Nv Derivados de piperidina / piperazina
JO2972B1 (en) * 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
CA2687912C (en) 2007-06-08 2015-11-03 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
SI2300013T1 (en) 2008-05-21 2018-03-30 Adriad Pharmacaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
PE20140572A1 (es) 2008-06-05 2014-05-16 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
AR074209A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
AR074210A1 (es) * 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
US8729265B2 (en) 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
EP2751110B1 (en) * 2011-10-14 2017-04-19 MedImmune Limited Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative and autoimmune diseases
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
KR102318875B1 (ko) 2019-03-19 2021-11-01 보로노이 주식회사 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물
CN112341468A (zh) * 2020-11-19 2021-02-09 烟台大学 一种1,4-苯并二氮杂*类化合物及其制备与功能化方法
WO2023204308A1 (ja) * 2022-04-22 2023-10-26 帝人ファーマ株式会社 オキサゼピン誘導体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2325440T3 (es) 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors

Also Published As

Publication number Publication date
WO2007096351A1 (de) 2007-08-30
EP1989198B1 (de) 2013-10-09
JP5306830B2 (ja) 2013-10-02
TW200804364A (en) 2008-01-16
EP1989198A1 (de) 2008-11-12
US20070207999A1 (en) 2007-09-06
US7569561B2 (en) 2009-08-04
CA2638095C (en) 2014-07-08
CA2638095A1 (en) 2007-08-30
JP2009527532A (ja) 2009-07-30

Similar Documents

Publication Publication Date Title
AR059594A1 (es) Derivados de 2,4-diaminopirimidinas
ES2352576T3 (es) Inhibidiores de la replicación del virus de la inmunodeficiencia humana.
PE20090884A1 (es) Compuestos de indol como activadores de glucoquinasa
PE20080841A1 (es) Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion
CO6231024A2 (es) Inhibidores de la polimera virica
PE20120593A1 (es) Derivados fusionados de pirimidin-4-ona como antagonistas del receptor de angiotensina ii y como agonistas del receptor ppar gamma
PE20110906A1 (es) Compuestos de arilo con sustituyentes heterociclicos como inhibidores hif
PE20141827A1 (es) Inhibidores de proteinas quinasas
AR055360A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
AR077468A1 (es) Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
AR045747A1 (es) Derivados de 2,4 di (hetero)-arilamino-pirimidina como zap-70 inhibidores
HRP20160096T1 (hr) Supstituirani derivati izokinolina
AR065322A1 (es) 2-aminooxazolinas comoligandos de taar1
PE20161021A1 (es) Derivados heterociclicos biciclicos como inhibidores de bromodominio
AR051195A1 (es) Piridinas como inhibidores de plk
AR069803A1 (es) 5- anilinoimiazopiridinas y metodos de uso
PE20120321A1 (es) Indazoles sustituidos con oxazol como inhibidores de pi3-quinasa
AR050365A1 (es) Compuestos inhibidores de multi- quinasa pirrolopirimidina aril- amino sustituidos.
AR059036A1 (es) Compuestos para el tratamiento de trastornos inflamatorios
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
AR071644A1 (es) Plaguicidas mesoionicos
AR084588A1 (es) Compuesto heterociclico fusionado y su uso para el control de plagas
PE20060010A1 (es) 2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPINAS 6-SUSTITUIDAS COMO AGONISTAS DEL RECEPTOR 5-HT2C
AR065718A1 (es) Compuestos heterociclicos nitrogenados,utiles en el diagnostico y tratamiento de trastornos hiperproliferativos.
AR066445A1 (es) Inhibidores de la proteina activadora de la 5- lipoxigenasa (flap)

Legal Events

Date Code Title Description
FB Suspension of granting procedure